Peptide News Digest

#Dignify-Therapeutics

1 story

Clinical Trials · View digest

Dignify Therapeutics Doses the First Volunteer With DTI-117, an On-Demand Peptide Meant to Trigger Bowel Emptying

Dignify Therapeutics of Research Triangle Park, North Carolina, dosed the first healthy volunteer on November 17 in a randomized, placebo-controlled Phase 1 study of DTI-117, a short-acting peptide that activates the NK2 receptor. The study will give single intramuscular doses to up to 40 people across up to five dose groups to test safety and how the body handles the drug. The NIH is funding the trial, and Dignify expects early results in early 2027. The company is developing DTI-117 for people with neurogenic bowel dysfunction, a condition that can leave them dependent on caregivers to empty their bowels.